Barron’s Top Weekend Stock Picks: CVS, Chewy, Apple And Confusion On Tesla’s China Plant Is Hurting Stock
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.
3 REITs With The Largest Recent Dividend Hikes
If you’re a serious real estate investment trust (REIT) investor, dividend hikes are like music to your ears. If you already own the stocks that are announcing increases, you’ll receive more money each month or quarter and have the satisfaction of knowing that your annual yield, based on your purchase price, is also rising.
Cathie Wood Adds $7M Of This Clinical-Stage Biotech, Trims Stake In CVS-Target Signify Health
Cathie Wood-led ARK Investment Management bought over 330,000 shares of clinical-stage biotechnology company Verve Therapeutics Inc (NASDAQ: VERV) at an estimated valuation of over $6.9 million, based on Tuesday’s closing price.
2 High-Yielding Grocery REITs Offer Best ‘Bang For Your Buck’ As A Global Recession Looms
Although the all-items index increased 7.7% for the twelve months ending October, this was the smallest 12-month increase since the period ending January 2022.
Meanwhile, food inflation increased by 0.6% in October to 10.9% unadjusted year-over-year.
It’s Cyber Monday: These 2 Mall REITs Are Offering Investors Better Than Average Yields
Using data gathered from Sept. 30, 2019, SP Global reported that over a 10-year period, real estate investment trusts (REITs) dealing with the retail industry had an average annual return of 10.1%.
Investors Show Optimism For Retail REITs On Black Friday
Retail stocks had mixed results during market hours Friday as early reports suggested the shopping holiday was off to a slower-than-normal start.
10 Analysts Have This to Say About CVS Health
Within the last quarter, CVS Health (NYSE:CVS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Morgan Stanley Assumes CVS Health at Overweight, Lowers Price Target of $119
Morgan Stanley analyst Erin Wright assumes CVS Health (NYSE:CVS) with a Overweight rating and lowers Price Target of $119.
Salesforce To $240? Plus RBC Capital Boosts PT For Autodesk
Jefferies cut the price target on Salesforce, Inc. (NYSE: CRM) from $250 to $240. Jefferies analyst Brent Thill maintained the stock with a Buy rating. Salesforce shares fell 1.2% to trade at $146.20 on Monday.